Javier J. Cruz-Dominguez

Sevilla, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Predictive Factors of Response and Real-World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort.

Predictive Factors of Response and Real-World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort.

Journal: International journal of dermatology

Published: October 03, 2025

Tralokinumab Effectiveness in Moderate-to-severe Atopic Dermatitis With Palmoplantar Eczema.

Tralokinumab Effectiveness in Moderate-to-severe Atopic Dermatitis With Palmoplantar Eczema.

Journal: Actas dermo-sifiliograficas

Published: February 13, 2025

Definition of the Concept of Super-responders in Atopic Dermatitis: A Spanish Delphi Consensus.

Definition of the Concept of Super-responders in Atopic Dermatitis: A Spanish Delphi Consensus.

Journal: Acta dermato-venereologica

Published: October 12, 2024

Parental Assessment of Infantile Hemangioma Cosmetic Clinical Outcomes: Results of the Spanish Hemangioma Nationwide Prospective Cohort.

Parental Assessment of Infantile Hemangioma Cosmetic Clinical Outcomes: Results of the Spanish Hemangioma Nationwide Prospective Cohort.

Journal: Actas dermo-sifiliograficas

Published: May 26, 2024

[Translated article] Real-World Clinical, Psychosocial and Financial Burden of Atopic Dermatitis: Results from the Spanish Cohort of the MEASURE-AD Trial.

[Translated article] Real-World Clinical, Psychosocial and Financial Burden of Atopic Dermatitis: Results from the Spanish Cohort of the MEASURE-AD Trial.

Journal: Actas dermo-sifiliograficas

Published: March 05, 2024

Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up.

Real-World Clinical Experience of Dupilumab in the Treatment of Chronic Palmo-Plantar Eczema in Patients with Moderate-Severe Atopic Dermatitis: 52-Week Follow-Up.

Journal: Dermatitis : contact, atopic, occupational, drug

Published: October 26, 2023

Upadacitinib for moderate to severe atopic dermatitis.

Upadacitinib for moderate to severe atopic dermatitis.

Journal: Immunotherapy

Published: May 17, 2023

[Translated article] Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study.

[Translated article] Selection of Quality Indicators for the Certification of Dermato-Oncology Units: The CUDERMA Project Delphi Consensus Study.

Journal: Actas dermo-sifiliograficas

Published: February 02, 2023

Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning.

Validation of a Questionnaire to Assess the Perception of Women with Atopic Dermatitis in Family Planning.

Journal: International journal of environmental research and public health

Published: August 07, 2022

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders).

Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders).

Journal: Life (Basel, Switzerland)

Published: July 31, 2022

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review.

Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review.

Journal: Life (Basel, Switzerland)

Published: July 17, 2022

Truncal Anesthesia for Hair Mesotherapy.

Truncal Anesthesia for Hair Mesotherapy.

Journal: Journal of cutaneous and aesthetic surgery

Published: June 03, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026